Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
38.75
+4.26 (12.35%)
At close: Sep 26, 2025, 4:00 PM EDT
38.96
+0.21 (0.54%)
After-hours: Sep 26, 2025, 7:57 PM EDT
Scholar Rock Holding Employees
Scholar Rock Holding had 128 employees as of December 31, 2024. The number of employees decreased by 22 or -14.67% compared to the previous year.
Employees
128
Change (1Y)
-22
Growth (1Y)
-14.67%
Revenue / Employee
n/a
Profits / Employee
-$2,466,305
Market Cap
3.72B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SRRK News
- 4 days ago - Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions - Seeking Alpha
- 4 days ago - Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection - Benzinga
- 4 days ago - Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 4 days ago - US FDA declines to approve Scholar Rock's muscle weakness drug - Reuters
- 4 days ago - FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility - Business Wire
- 15 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment - Business Wire
- 7 weeks ago - Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript - Seeking Alpha